Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-005745
Filing Date
2020-05-07
Accepted
2020-05-07 16:31:19
Documents
60
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ettx-20200331x10q.htm 10-Q 1135472
2 EX-10.1 ettx-20200331ex101691ded.htm EX-10.1 114861
3 EX-10.2 ettx-20200331ex1023d4264.htm EX-10.2 108928
4 EX-10.3 ettx-20200331ex1037e77ce.htm EX-10.3 22375
5 EX-31.1 ettx-20200331ex311372a18.htm EX-31.1 15457
6 EX-31.2 ettx-20200331ex312bc8c51.htm EX-31.2 14505
7 EX-32.1 ettx-20200331ex3213c3025.htm EX-32.1 9967
  Complete submission text file 0001558370-20-005745.txt   4641350

Data Files

Seq Description Document Type Size
8 EX-101.INS ettx-20200331.xml EX-101.INS 813589
9 EX-101.SCH ettx-20200331.xsd EX-101.SCH 43839
10 EX-101.CAL ettx-20200331_cal.xml EX-101.CAL 43497
11 EX-101.DEF ettx-20200331_def.xml EX-101.DEF 137861
12 EX-101.LAB ettx-20200331_lab.xml EX-101.LAB 370707
13 EX-101.PRE ettx-20200331_pre.xml EX-101.PRE 261065
Mailing Address 35 GATEHOUSE DRIVE WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE WALTHAM MA 02451 (781) 810-0120
Entasis Therapeutics Holdings Inc. (Filer) CIK: 0001724344 (see all company filings)

EIN.: 824592913 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38670 | Film No.: 20856964
SIC: 2834 Pharmaceutical Preparations